Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE9A | O76083 | 3/20 | 0.49 |
| ▸ | PDE1A | P54750 | 3/20 | 0.49 |
| ▸ | PDE1B | Q01064 | 3/20 | 0.49 |
| ▸ | PDE1C | Q14123 | 3/20 | 0.49 |
| ▸ | PDE5A | O76074 | 1/20 | 0.49 |
| ▸ | MPO | P05164 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6368253 | 0.89 | PDE9A (0.52) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6367439 | 0.87 | PDE9A (0.50) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6367359 | 0.87 | PDE9A (0.50) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6366773 | 0.86 | PDE9A (0.51) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6367469 | 0.85 | PDE9A (0.52) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6367545 | 0.84 | PDE9A (0.53) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL3494823 | 0.82 | PDE5A (0.71) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6366904 | 0.82 | PDE9A (0.50) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL3492432 | 0.80 | PDE9A (0.73) | PDE9APDE1APDE1BPDE1CPDE5A | |
| SCHEMBL6366064 | 0.79 | GRIN1 (0.47) | PDE9APDE1APDE1BPDE1CPDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967204-B2 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC | 2005-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | PDE9A 3/4885PDE1A 46/4885PDE1B 39/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.